Cargando…
From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development
The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SA...
Autores principales: | Ma, Cuiqing, Su, Shan, Wang, Jiachao, Wei, Lin, Du, Lanying, Jiang, Shibo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Institut Pasteur. Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211703/ https://www.ncbi.nlm.nih.gov/pubmed/32437926 http://dx.doi.org/10.1016/j.micinf.2020.05.004 |
Ejemplares similares
-
Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013) -
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020) -
Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2
por: Jiang, Shibo, et al.
Publicado: (2020) -
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020) -
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
por: Chen, Yanjia, et al.
Publicado: (2022)